J & J Settlement Pays Off For Nation’s Capital

The government’s recent massive settlement with Johnson & Johnson is paying dividends for the residents of Washington, D.C.

The District of Columbia’s Medicaid program will receive more than $3 million out of the $1.2 billion settlement, which resolved four qui tam cases filed in federal court in the Eastern District of Pennsylvania.

The suits contended that Johnson & Johnson and subsidiary Janssen Pharmaceuticals, Inc., engaged in off-label promotion of antipsychotic drugs Risperdal and Invega.

Contact one of our

Experienced Attorneys

If you are aware of any person, corporation or entity that you think may be violating the Federal False Claims Act or a State False Claims Act, contact us today.